The Global Iopamidol API Market was valued at USD 252.54 million in 2023 and is projected to reach USD 326.99 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 4.40% during the forecast period (2024–2029). This growth is driven by rising demand for contrast-enhanced medical imaging procedures and the expansion of healthcare infrastructure in emerging economies.

As the healthcare industry increasingly relies on advanced diagnostic techniques, the importance of high-quality contrast agents has never been greater. Iopamidol, a non-ionic, low-osmolar contrast medium, has become essential for X-ray and CT scan procedures worldwide. In this analysis, we examine the Top 10 Companies in the Iopamidol API Industry—key manufacturers and innovators shaping this crucial pharmaceutical segment.

---

🔟 1. Bracco Imaging S.p.A.

Headquarters: Milan, Italy
Key Offering: Original Iopamidol API and contrast media formulations

Bracco Imaging, a subsidiary of Bracco Group, is a global leader in diagnostic imaging with a strong portfolio of contrast media products. The company not only produces Iopamidol API but also develops finished formulations for medical imaging applications.

Innovation Highlights:

• Pioneer in non-ionic contrast media development

• Ongoing research in next-generation contrast agents

• Global manufacturing footprint with stringent quality standards

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/259780/global-iopamidol-api-market-2024-192

---

9️⃣ 2. Guerbet Group

Headquarters: Villepinte, France
Key Offering: Contrast media solutions including Iopamidol-based products

Guerbet specializes in medical imaging with a comprehensive portfolio of contrast agents. The company has manufacturing facilities across Europe, Asia, and North America, ensuring global supply chain reliability.

Innovation Highlights:

• Strong focus on patient safety in contrast media formulation

• Continuous investment in R&D for improved imaging agents

---

8️⃣ 3. Hengrui Medicine

Headquarters: Lianyungang, China
Key Offering: Generic Iopamidol API and formulations

As one of China’s leading pharmaceutical companies, Hengrui Medicine has become a significant player in the Iopamidol API market with its cost-effective production capabilities.

Innovation Highlights:

• Extensive production capacity in China

• Growing exports to emerging markets

---

7️⃣ 4. Stellite

Headquarters: Mumbai, India
Key Offering: Generic Iopamidol API

Stellite has established itself as a reliable manufacturer of contrast media APIs with facilities that comply with international GMP standards.

Innovation Highlights:

• Strategic focus on cost optimization

• Expanding presence in Asian and African markets

---

6️⃣ 5. Jiangsu Hansoh Pharmaceutical Group

Headquarters: Lianyungang, China
Key Offering: Iopamidol API and formulations

Hansoh has rapidly grown its pharmaceutical business including contrast media production, with increasing exports to international markets.

Innovation Highlights:

• Vertically integrated production capabilities

• Continuous process optimization initiatives

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/259780/global-iopamidol-api-market-2024-192

---

5️⃣ 6. Sanochemia Pharmazeutika AG

Headquarters: Vienna, Austria
Key Offering: Contrast media APIs including Iopamidol

With decades of experience in contrast media, Sanochemia maintains strict European quality standards across its production facilities.

Innovation Highlights:

• Specialized in neurological contrast applications

• Strong regulatory compliance focus

---

4️⃣ 7. Liebel-Flarsheim Company

Headquarters: Raleigh, North Carolina, USA
Key Offering: Iopamidol-based contrast agents

As a subsidiary of Mallinckrodt Pharmaceuticals, Liebel-Flarsheim specializes in contrast media products for radiology applications.

Innovation Highlights:

• Advanced formulation technologies

• Strong presence in North American healthcare systems

---

3️⃣ 8. Daiichi Sankyo

Headquarters: Tokyo, Japan
Key Offering: Contrast media solutions including Iopamidol API

The Japanese pharmaceutical giant has significant expertise in diagnostic imaging products with a focus on the Asian market.

Innovation Highlights:

• Innovative packaging and delivery systems

• High-volume production capabilities

---

2️⃣ 9. Shanghai Huiheng Pharmaceutical

Headquarters: Shanghai, China
Key Offering: Generic Iopamidol API

This emerging Chinese manufacturer has been expanding its production capacity for contrast media APIs to meet growing domestic and international demand.

Innovation Highlights:

• Focus on cost-effective production

• Strategic partnerships with formulation manufacturers

---

1️⃣ 10. General Electric Healthcare

Headquarters: Chicago, Illinois, USA
Key Offering: Integrated imaging solutions including Iopamidol-based contrast agents

GE Healthcare leverages its extensive diagnostic imaging expertise to provide comprehensive contrast media solutions alongside its imaging equipment.

Innovation Highlights:

• Synergy between imaging technology and contrast media development

• Global distribution network

Read Full Report Here: https://www.24chemicalresearch.com/reports/259780/global-iopamidol-api-market-2024-192

---

📈 Outlook: The Future of Iopamidol API Industry

The Iopamidol API market is evolving as healthcare systems worldwide continue to expand diagnostic imaging capabilities. With aging populations and increasing prevalence of chronic diseases requiring imaging diagnostics, demand for high-quality contrast agents remains strong.

🔄 Key Trends Shaping the Market:

• Growing adoption of CT imaging procedures globally

• Increasing healthcare expenditures in emerging economies

• Stringent quality requirements for contrast media APIs

• Shift toward automated manufacturing processes

Read Full Report Here: https://www.24chemicalresearch.com/reports/259780/global-iopamidol-api-market-2024-192

The companies profiled above are not just supplying critical pharmaceutical ingredients—they’re enabling more accurate diagnoses and better patient outcomes worldwide.